Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | F2 | P00734 | 11/20 | 0.47 |
| ▸ | F10 | P00742 | 4/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.47 |
| ▸ | EP300 | Q09472 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | F12 | P00748 | 2/20 | 0.44 |
| ▸ | F7 | P08709 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6925078 | 0.90 | ALDH1A1 (0.61) | ALDH1A1F2F10PRSS1PRSS2 | |
| SCHEMBL6926479 | 0.86 | F2 (0.60) | ALDH1A1F2F10PRSS1PRSS2 | |
| SCHEMBL6925422 | 0.84 | ALDH1A1 (0.62) | ALDH1A1F2F10PRSS1PRSS2 | |
| SCHEMBL6923255 | 0.79 | HTR2C (0.46) | ALDH1A1EPHX2 | |
| SCHEMBL6925564 | 0.77 | EGFR (0.45) | ALDH1A1EP300CREBBP | |
| SCHEMBL6924847 | 0.76 | F2 (0.49) | ALDH1A1F2F10PRSS1PRSS2 | |
| SCHEMBL6924003 | 0.75 | ALDH1A1 (0.47) | ALDH1A1F2F10PRSS1PRSS2 | |
| SCHEMBL6921229 | 0.75 | F2 (0.60) | ALDH1A1F2F10PRSS1PRSS2 | |
| SCHEMBL6926606 | 0.75 | ALDH1A1 (0.71) | ALDH1A1F2F10PRSS1PRSS2 | |
| SCHEMBL13374829 | 0.73 | ALDH1A1 (0.74) | ALDH1A1F2MEN1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6515011-B2 | Anticoagulants | MERCK & CO., INC. | 2003-02-04 | — | — | US | disclosed |
| US-20020119992-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119992-A1 | Thrombin inhibitors | SERPINC1, F2, TFPI | ALDH1A1 4773/4885F2 2/4885F10 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.